Teva Considers Selling Oncology Biz

Source: Bloomberg

Apr 27, 2017

Teva, looking to reduce debt, is exploring a sale of its specialty cancer treatments, says Bloomberg sources.

Bloomberg sources also say sale considerations are preliminary and Teva could change its mind. Revenue from the oncology division fell 5 percent to $1.14 billion last year. 

The generic giant's debt continues to grow as sales are hit by competition from rival teherapies. Teva's CEO Erez Vigodman resigned in February as Teva struggled through a series of missteps and contraversies.

Read the Bloomberg story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments